Chemical Identity And Biological Role — Background and Details

By Editorial Desk · published 2026-06-08 · last reviewed 2026-06-27 · Data

Everything below concerns Stability. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-06-27. Where a claim depends on a specific study, the study is described rather than over-claimed.

Chemical Identity and Biological Role

Small amounts of NMN occur in some foods, including certain vegetables, fruits, and animal products, though the quantities are generally low and variable. Human cells also synthesize NMN internally from nicotinamide and other precursors. Research interest increased after studies examined whether raising NAD+ levels affects metabolism and aging-related pathways in animals. Evidence in humans remains limited and mixed for many outcomes, and questions about effective absorption, tissue delivery, and long-term effects are still open. Regulatory status differs by country, with some markets treating NMN as a supplement ingredient and others restricting its sale.

Nicotinamide mononucleotide, usually shortened to NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide base linked to a ribose sugar that carries a phosphate group. In cells, NMN serves as an intermediate in the salvage pathway that produces nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in many oxidation-reduction reactions, NMN sits near central metabolic processes. The compound is not a drug in most jurisdictions and is discussed mainly in biochemistry and nutrition research.

The term NMN commonly refers to the beta isomer, in which the nicotinamide group is attached to the ribose through a beta-glycosidic bond. Commercial material may be supplied as the free acid or as a salt, such as a sodium salt, which affects molecular weight and water solubility. Related compounds include nicotinamide riboside and NAD+ itself, but these are distinct molecules with different formulas and cellular handling. Laboratory research often uses the beta form because it matches the naturally occurring configuration found in biological systems.

Stability, Analysis, and Verification

Commercial NMN is produced through enzymatic or chemical routes, and the resulting material can vary in purity, counterion, and residual solvent content. Buyers typically rely on certificates of analysis, but independent verification through third-party laboratories provides stronger assurance. Regulatory treatment differs by country; in the United States, NMN has been subject to shifting guidance about its status as a dietary supplement, while other markets permit sales under local rules. No universal pharmacopeial monograph exists for NMN, so specifications often come from suppliers, research protocols, or regional requirements.

Solid NMN is generally handled as a moisture-sensitive compound. Dry material stored desiccated at low temperature, protected from light, tends to remain stable for extended periods. Aqueous solutions are less stable and can undergo hydrolysis, especially at elevated temperature or alkaline pH. The anomeric form also matters: beta-NMN is the naturally occurring form, while alpha-NMN can appear as a synthetic impurity. Purity and storage conditions therefore influence both analytical results and experimental reproducibility.

Nmn at a glance

Biochemical Identity and Pathway Role

Beyond its intracellular synthesis, NMN can be taken up from the extracellular environment, although the routes are still debated. Some evidence points to direct transport into cells through specific transporters, while other work suggests dephosphorylation to nicotinamide riboside followed by cellular uptake. Once inside, NMN can be converted to NAD+ by NMN adenylyltransferases; the relative contribution of these routes may differ by tissue, species, and experimental conditions. Researchers continue to investigate which mechanisms dominate in intact organisms and how they affect measured NAD+ levels. Direct measurement in tissues remains technically challenging because NMN can be rapidly metabolized during sample collection.

NMN occurs in many living systems, including bacteria, yeast, plants, and mammals. Dietary sources are present in foods such as edamame, avocado, broccoli, and various meats, but amounts vary widely and are generally lower than those used in research settings. Laboratory production often relies on enzymatic synthesis or chemical phosphorylation of nicotinamide riboside, and commercial material is typically supplied as a white to off-white powder. Because NMN is hygroscopic and sensitive to heat, moisture, and pH extremes, its handling requires care to preserve identity and purity. Aqueous preparation should be done with attention to pH and temperature to limit hydrolysis.

Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure consists of a nicotinamide ring linked to ribose phosphate, and the compound serves as an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+. In this pathway, nicotinamide phosphoribosyltransferase converts nicotinamide and phosphoribosyl pyrophosphate into NMN, after which NMN adenylyltransferase attaches an adenylate group to produce NAD+. Because NAD+ participates in redox reactions and signaling, NMN occupies a central position in cellular metabolism. The molecule is distinct from nicotinamide riboside, though the two are related in NAD+ precursor research.

Related pages on this site

• Lightweight workbook
• Robust summary
• Scalable report
• Scalable digest
• Modern overview
• Durable dataset
• Modern workbook
• Durable handbook

Stability, Handling, and Analysis

NMN is a polar, water-soluble nucleotide. In solid form it is usually a white to off-white powder. The compound is sensitive to heat, light, moisture, and extremes of pH, and aqueous solutions tend to degrade faster than dry material. Recommended storage for research samples is typically -20 °C or below in a sealed, desiccated container protected from light. Repeated freeze-thaw cycles should be avoided, and these handling practices help maintain identity and purity during laboratory use.

Analytical identification of NMN commonly uses high-performance liquid chromatography with ultraviolet detection, liquid chromatography-mass spectrometry, and nuclear magnetic resonance spectroscopy; HPLC can estimate purity by peak area, while mass spectrometry confirms molecular mass and fragmentation. NMR provides structural confirmation. Because NMN is charged, ion-pairing reagents or hydrophilic interaction liquid chromatography columns can improve retention and peak shape. In biological samples, LC-MS/MS with stable isotope internal standards is often used to quantify NMN and related NAD+ metabolites. Method validation is important because matrix effects and rapid enzymatic interconversion can complicate measurements.

Further detail

== RF value, solutes, and solvents == The retardation factor (RF) may be defined as the ratio of the distance travelled by the solute to the distance travelled by the solvent. It is used in chromatography to quantify the amount of retardation of a sample in a stationary phase relative to a mobile phase. RF values are usually expressed as a fraction of two decimal places.

The legacy of the USSR remains a controversial topic. The socio-economic nature of communist states such as the USSR, especially under Stalin, has also been much debated, varyingly being labelled a form of bureaucratic collectivism, state capitalism, state socialism, or a totally unique mode of production. The USSR implemented a broad range of policies over a long period of time, with a large amount of conflicting policies being implemented by different leaders. Some have a positive view of it whilst others are critical towards the country, calling it a repressive oligarchy. The opinions on the USSR are complex and have changed over time, with different generations having different views on the matter as well as on Soviet policies corresponding to separate time periods during its history.

== Health facility workload == The workload of a health facility is often used to indicate its size. Large health facilities are those with a greater patient load. In Australia the workload of a health facility is used to determine the level of government funding provided to that facility. The government measures a facility (or health practice) in terms of its standard whole patient equivalent (SWPE). The SWPE calculation is determined by analysis of the patients that attend that facility. The calculation takes into account the proportion of health services (in dollars) rendered at that facility relative to others that each patient attends. It includes a weighting factor based on each patients' demography to account for the varied levels of services required by patients depending on their gender and age. The premise of weighting is that patients require different levels of health services depending on their age and gender. For example, the average male patient requires fewer consultations than his older and infant counterparts. The table shows the weighting factors used in the standardization of workloads. Table: Age by Sex Weights for SWPE Standardisation

=== Sanger sequencing-based decoding === Although many authors implicitly envisaged a traditional Sanger sequencing-based decoding, the number of codes to sequence simply according to the complexity of the library is definitely an unrealistic task for a traditional Sanger sequencing approach. Nevertheless, the implementation of Sanger sequencing for decoding DNA-encoded chemical libraries in high-throughput fashion was the first to be described. After selection and PCR amplification of the DNA-tags of the library compounds, concatamers containing multiple coding sequences were generated and ligated into a vector. Following Sanger sequencing of a representative number of the resulting colonies revealed the frequencies of the codes present in the DNA-encoded library sample before and after selection.

=== Interest during COVID-19 pandemic === Sertraline has been the most sought-after antidepressant worldwide before, during, and after the COVID-19 pandemic, according to Google Trends data. The pandemic has led to an increase in searches for antidepressants, with sertraline, fluoxetine, duloxetine, and venlafaxine showing the highest search volumes, whereas searches of citalopram decreased during the pandemic.

Sources: en.wikipedia.org

Supporting material

Olipudase alfa, sold under the brand name Xenpozyme, is a medication used for the treatment of non-central nervous system (CNS) manifestations of acid sphingomyelinase deficiency type A/B or type B. The most common side events include infections, infusion-related reactions, or gastrointestinal complaints (disease signs and symptoms in children). Historically referred to as Niemann-Pick disease types A (NPD A) and B (NPD B), acid sphingomyelinase deficiency is a genetic disorder. It belongs to the larger family of metabolic disorders called lysosomal storage diseases, in which fats build up within the parts of the body's cells that break down nutrients and other materials. This affects the way cells work and causes them to die, affecting normal functioning of tissues and organs. Acid sphingomyelinase deficiency is seriously debilitating and life-threatening since the build-up of fatty substances can cause brain damage and swelling of organs such as liver and spleen. Xenpozyme is the first acid sphingomyelinase deficiency-specific treatment. The replacement enzyme is produced by a method known as recombinant DNA technology: it is made by cells into which a gene (DNA) has been introduced, that enables them to produce the enzyme. Olipudase alfa was approved for medical use in Japan in March 2022, in the European Union in June 2022, and in the United States in August 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Subsequent experiments showed that the 19 "cold" amino acids were not necessary and that the protein product had the biochemical characteristics of polyphenylalanine, demonstrating that a chain of repeated uracil bases produced a protein chain made solely of the repeating amino acid phenylalanine. While the experiment did not determine the number of bases per codon, it was consistent with the triplet codon UUU coding for phenylalanine. In analogous experiments with other synthetic RNAs, they found that poly-C directed synthesis of polyproline. Nirenberg recounts that the labs of Severo Ochoa and James Watson had earlier done similar experiments with poly-A, but failed to detect protein synthesis because polylysine (unlike most proteins) is soluble in trichloroacetic acid. Further, using synthetic RNAs that randomly incorporated two bases at different ratios, they produced proteins containing more than one type of amino acid, from which they could deduce the triplet nature of the genetic code and narrow down the codon possibilities for other amino acids. Nirenberg's group eventually decoded all the amino acid codons by 1966, however this required additional ingenious experimental methods (see Nirenberg and Leder experiment).

Kimon Georgiev became prime minister on 19 May 1934, after the coup d'état. He served as Minister of Foreign Affairs and Religious Affairs (19-23 May 1934) and Minister of Justice (23 May 1934 – 22 January 1935) and temporarily served as Minister of War on 19 May 1934. Kimon Georgiev led the new Cabinet, which was primarily made up of Zveno and Military League representatives. Although they denounced the coup, the other bourgeois parties and the non-fascist bourgeois parties accepted it. The BCP called it a fascist coup, but they were unable to put up a united front to fight it due to mistakes in secretarian doctrine. The coup's perpetrators said in their manifesto that a "national supra-party power" would be established. They abolished the Parliament, dissolved the IMRO, and restructured the governmental apparatus on a fascist basis.

=== Functionally characterized genes involved in AGP glycosylation === Bioinformatics analysis using mammalian β-1,3-galactosyltransferase (GalT) sequences as templates suggested involvement of the Carbohydrate-Active enZYmes (CAZy) glycosyltransferase (GT) 31 family in the synthesis of the galactan chains of the AG backbone. Members of the GT31 family have been grouped into 11 clades, with four clades being plant-specific: Clades 1, 7, 10, and 11. Clades 1 and 11 domains and motifs are not well-defined; while Clades 7 and 10 have domain similarities with proteins of known GalT function in mammalian systems. Clade 7 proteins contain both GalT and galectin domains, while Clade 10 proteins contain a GalT-specific domain. The galectin domain is proposed to allow the GalT to bind to the first Gal residue on the polypeptide backbone of AGPs; thus, determining the position of subsequent Gal residues on the protein backbone, similar to the activity of human galectin domain-containing proteins. Eight enzymes belonging to the GT31 family demonstrated the ability to place the first Gal residue onto Hyp residues in AGP core proteins. These enzymes are named GALT2, GALT3, GALT4, GALT5, GALT6, which are Clade 7 members, and HPGT1, HPGT2, and HPGT3, which are Clade 10 members. Preliminary enzyme substrate specificity studies demonstrated that another GT31 Clade 10 enzyme, At1g77810, had β-1,3-GalT activity. A GT31 Clade 10 gene, KNS4/UPEX1, encodes a β-1,3-GalT capable of synthesizing β-1,3-Gal linkages found in type II AGs present in AGPs and/or pectic rhamnogalacturonan I (RG-I).

Sources: en.wikipedia.org

Supporting material

The coagulation cascade of secondary hemostasis has two initial pathways which lead to fibrin formation. These are the contact activation pathway (also known as the intrinsic pathway), and the tissue factor pathway (also known as the extrinsic pathway), which both lead to the same fundamental reactions that produce fibrin. It was previously thought that the two pathways of coagulation cascade were of equal importance, but it is now known that the primary pathway for the initiation of blood coagulation is the tissue factor (extrinsic) pathway. The pathways are a series of reactions, in which a zymogen (inactive enzyme precursor) of a serine protease and its glycoprotein co-factor are activated to become active components that then catalyze the next reaction in the cascade, ultimately resulting in cross-linked fibrin. Coagulation factors are generally indicated by Roman numerals, with a lowercase a appended to indicate an active form. The coagulation factors are generally enzymes called serine proteases, which act by cleaving downstream proteins. The exceptions are tissue factor, FIV, FV, FVIII, FXIII. Tissue factor, FV, and FVIII are glycoproteins; Factor IV is a calcium ion; and Factor XIII is a transglutaminase. The coagulation factors circulate as inactive zymogens. The coagulation cascade is therefore classically divided into three pathways. The tissue factor and contact activation pathways both activate the "final common pathway" of factor X, thrombin and fibrin.

==== Hamaker interaction ==== As nanoparticle interactions take place on a nanoscale, the particle interactions must be scaled similarly. Hamaker interactions take into account the polarization characteristics of a large number of nearby particles and the effects they have on each other. Hamaker interactions sum all of the forces between all particles and the solvent(s) involved in the system. While Hamaker theory generally describes a macroscopic system, the vast number of nanoparticles in a self-assembling system allows the term to be applicable. Hamaker constants for nanoparticles are calculated using Lifshitz theory, and can often be found in literature.

== History == α-MSH was first isolated in the 1950s and its primary structure determined. By the 1960s, its role in promoting melanin diffusion was understood. In the 1980s, the University of Arizona synthesised more potent analogs of a-MSH, including afamelanotide. Afamelanotide was initially named melano-tan (or melanotan-I) due to its ability to tan skin with minimal sun exposure. Later, melanotan-II was synthesised. Following initial development at the University of Arizona as a sunless tanning agent, the Australian company Clinuvel conducted further clinical trials in that and other indications, and brought the drug to market in the European Union, the United States, and Australia. To pursue the tanning agent, melanotan-I was licensed by Competitive Technologies, a technology transfer company operating on behalf of University of Arizona, to an Australian startup called Epitan, which changed its name to Clinuvel in 2006. Early clinical trials showed that the peptide had to be injected about ten times a day due to its short half-life, so the company collaborated with Southern Research in the US to develop a depot formulation that would be injected under the skin, and release the peptide slowly. This was done by 2004. Multiple studies on the clinical effects of afamelanotide were conducted. According to ClinicalTrials.gov, Clinuvel sponsored several trials between 2007 and 2011 to explore its effects on erythropoietic protoporphyria, vitiligo, polymorphous light eruption, solar urticaria and acne vulgaris.

Sources: en.wikipedia.org

Frequently asked questions